Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 850831, 6 pages
http://dx.doi.org/10.1155/2014/850831
Review Article

Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency

1Pediatrics and Neonatology Unit, Imola Hospital, Via Montericco 4, 40026 Imola, Italy
2DIMEC, Neonatology and Neonatal Intensive Care Unit, St. Orsola-Malpighi Hospital, Via Massarenti 11, University of Bologna, 40138 Bologna, Italy
3DIMES, Clinical Microbiology Unit, Laboratory of Virology, St. Orsola-Malpighi Hospital, Via Massarenti 9, University of Bologna, Bologna, Italy

Received 5 May 2014; Revised 11 June 2014; Accepted 12 June 2014; Published 25 June 2014

Academic Editor: Roshini Sarah Abraham

Copyright © 2014 Marcello Lanari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. F. Simoes, “Respiratory syncytial virus infection,” The Lancet, vol. 354, no. 9181, pp. 847–852, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Nair, V. R. Verma, E. Theodoratou et al., “An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children,” BMC Public Health, vol. 11, supplement 3, article S30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. B. Hall, G. A. Weinberg, M. K. Iwane et al., “The Burden of respiratory syncytial virus infection in young children,” The New England Journal of Medicine, vol. 360, no. 6, pp. 588–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. L. C. Paramore, V. Ciuryla, G. Ciesla, and L. Liu, “Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases,” PharmacoEconomics, vol. 22, no. 5, pp. 275–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. O. Blanken, M. M. Rovers, J. M. Molenaar et al., “Respiratory syncytial virus and recurrent wheeze in healthy preterm infants,” The New England Journal of Medicine, vol. 368, no. 19, pp. 1791–1799, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. W. W. Thompson, D. K. Shay, E. Weintraub et al., “Mortality associated with influenza and respiratory syncytial virus in the United States,” The Journal of the American Medical Association, vol. 289, no. 2, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Asner, D. Stephens, P. Pedulla, S. E. Richardson, J. Robinson, and U. Allen, “Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children,” Pediatric Infectious Disease Journal, vol. 32, no. 10, pp. 1073–1076, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Choi, E. H. Choi, H. J. Kang et al., “Respiratory viral infections after hematopoietic stem cell transplantation in children,” Journal of Korean Medical Science, vol. 28, no. 1, pp. 36–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gaboli, O. A. de la Cruz, M. I. de Agüero, A. Moreno-Galdó, G. P. Pérez, and M. S. de Querol, “Use of palivizumab in infants and young children with severe respiratory disease: a delphi study,” Pediatric Pulmonology, vol. 49, no. 5, pp. 490–502, 2014. View at Publisher · View at Google Scholar
  10. Y. J. Kim, M. Boeckh, and J. A. Englund, “Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection,” Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 2, pp. 222–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Resch, P. Manzoni, and M. Lanari, “Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes,” Paediatric Respiratory Reviews, vol. 10, no. 3, pp. 148–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Thorburn, “Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection,” Archives of Disease in Childhood, vol. 94, no. 2, pp. 99–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Sommer, B. Resch, and E. A. Simões, “Risk factors for severe respiratory syncytial virus lower respiratory tract infection,” Open Microbiology Journal, vol. 5, no. 2, pp. 144–154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Martinello, M. D. Chen, C. Weibel, and J. S. Kahn, “Correlation between respiratory syncytial virus genotype and severity of illness,” Journal of Infectious Diseases, vol. 186, no. 6, pp. 839–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Gilca, G. de Serres, M. Tremblay et al., “Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons,” Journal of Infectious Diseases, vol. 193, no. 1, pp. 54–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Vandini, L. Corvaglia, R. Alessandroni et al., “Respiratory syncytial virus infection in infants and correlation with meteorological factors and air pollutants,” Italian Journal of Pediatrics, vol. 39, no. 1, article 1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. Meerhoff, J. W. Paget, J. L. Kimpen, and F. Schellevis, “Variation of respiratory syncytial virus and the relation with meteorological factors in different winter seasons,” Pediatric Infectious Disease Journal, vol. 28, no. 10, pp. 860–866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Noyola and P. B. Mandeville, “Effect of climatological factors on respiratory syncytial virus epidemics,” Epidemiology and Infection, vol. 136, no. 10, pp. 1328–1332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Garcia-Barreno, C. Palomo, C. Penas, T. Delgado, P. Perez-Brena, and J. A. Melero, “Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins,” Journal of Virology, vol. 63, no. 2, pp. 925–932, 1989. View at Google Scholar · View at Scopus
  20. C. le Nouën, P. Hillyer, S. Munir et al., “Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells,” PLoS ONE, vol. 5, no. 11, Article ID e15017, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. R. Groothuis, J. M. Hoopes, and V. G. H. Jessie, “Prevention of serious respiratory syncytial virus-related illness. I: disease pathogenesis and early attempts at prevention,” Advances in Therapy, vol. 28, no. 2, pp. 91–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. O. Ohuma, E. A. Okiro, R. Ochola et al., “The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease,” American Journal of Epidemiology, vol. 176, no. 9, pp. 794–802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. Piedra, A. M. Jewell, S. G. Cron, R. L. Atmar, and W. P. Glezen, “Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies,” Vaccine, vol. 21, no. 24, pp. 3479–3482, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Mejías, S. Chávez-Bueno, A. M. Ríos et al., “Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus Potency,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4700–4707, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. B. Domachowske and H. F. Rosenberg, “Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment,” Clinical Microbiology Reviews, vol. 12, no. 2, pp. 298–309, 1999. View at Google Scholar · View at Scopus
  26. D. Kruijsen, M. J. Bakkers, N. O. Van Uden et al., “Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections,” Journal of Immunology, vol. 185, no. 11, pp. 6489–6498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. K. McIntosh, H. B. Masters, I. Orr, R. K. Chao, and R. M. Barkin, “The immunologic response to infection with respiratory syncytial virus in infants,” Journal of Infectious Diseases, vol. 138, no. 1, pp. 24–32, 1978. View at Publisher · View at Google Scholar · View at Scopus
  28. K. McIntosh, J. McQuillin, and P. S. Gardner, “Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection,” Infection and Immunity, vol. 23, no. 2, pp. 276–281, 1979. View at Google Scholar · View at Scopus
  29. B. S. Graham, G. S. Henderson, Y. W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley, “Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus,” The Journal of Immunology, vol. 151, no. 4, pp. 2032–2040, 1993. View at Google Scholar · View at Scopus
  30. B. J. Law, E. E. Wang, N. MacDonald et al., “Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database,” Pediatrics, vol. 99, no. 3, article E7, 1997. View at Google Scholar · View at Scopus
  31. A. F. Christiaansen, C. J. Knudson, K. A. Weiss, and S. M. Varga, “The CD4 T cell response to respiratory syncytial virus infection,” Immunologic Research, 2014. View at Publisher · View at Google Scholar
  32. D. You, N. Marr, J. Saravia, B. Shrestha, G. I. Lee, and S. E. Turvey, “IL-4Ra on CD4+ T cells plays a pathogenic role in respiratory syncytial virus reinfection in mice infected initially as neonates,” Journal of Leukocyte Biology, vol. 93, no. 6, pp. 933–942, 2013. View at Google Scholar
  33. R. B. Fulton, D. K. Meyerholz, and S. M. Varga, “Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection,” Journal of Immunology, vol. 185, no. 4, pp. 2382–2392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. C. P. Lee, J. A. E. Harker, J. S. Tregoning et al., “CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection,” Journal of Virology, vol. 84, no. 17, pp. 8790–8798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. K. A. Weiss, A. F. Christiaansen, R. B. Fulton, D. K. Meyerholz, and S. M. Varga, “Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection,” The Journal of Immunology, vol. 187, no. 6, pp. 3145–3154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Chin, R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette, “Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population,” American Journal of Epidemiology, vol. 89, no. 4, pp. 449–463, 1969. View at Google Scholar · View at Scopus
  37. E. M. Castilow and S. M. Varga, “Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination,” Future Virology, vol. 3, no. 5, pp. 445–454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Z. Kapikian, R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart, “An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine,” The American Journal of Epidemiology, vol. 89, no. 4, pp. 405–421, 1969. View at Google Scholar · View at Scopus
  39. H. W. Kim, J. G. Canchola, C. D. Brandt et al., “Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine,” American Journal of Epidemiology, vol. 89, no. 4, pp. 422–434, 1969. View at Google Scholar · View at Scopus
  40. Y. Murata, “Respiratory syncytial virus vaccine development,” Clinics in Laboratory Medicine, vol. 29, no. 4, pp. 725–739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. W. H. Alwan, F. M. Record, and P. J. M. Openshaw, “CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells,” Clinical and Experimental Immunology, vol. 88, no. 3, pp. 527–536, 1992. View at Google Scholar · View at Scopus
  42. Y. Tang and B. S. Graham, “T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice,” The Journal of Clinical Investigation, vol. 99, no. 9, pp. 2183–2191, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. B. N. A. Crooks, C. E. Taylor, A. J. L. Turner et al., “Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit,” Bone Marrow Transplantation, vol. 26, no. 10, pp. 1097–1102, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Al-Herz and L. D. Notarangelo, “Classification of primary immunodeficiency disorders: one-fits-all does not help anymore,” Clinical Immunology, vol. 144, no. 1, pp. 24–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. W. Baker, W. J. Grossman, R. H. Laessig et al., “Development of a routine newborn screening protocol for severe combined immunodeficiency,” Journal of Allergy and Clinical Immunology, vol. 124, no. 3, pp. 522–527, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. L. D. Notarangelo, “Primary immunodeficiencies,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, supplement 2, pp. S182–S194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Al-Herz and M. A. A. Moussa, “Survival and predictors of death among primary immunodeficient patients: a registry-based study,” Journal of Clinical Immunology, vol. 32, no. 3, pp. 467–473, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. Lo, G. M. Lee, N. Gunawardane, S. K. Burchett, C. S. Lachenauer, and L. E. Lehmann, “The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy,” Pediatric Transplantation, vol. 17, no. 2, pp. 133–143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Shachor-Meyouhas, I. Zaidman, Z. Kra-Oz, N. Arad-Cohen, and I. Kassis, “Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department,” Journal of Pediatric Hematology/Oncology, vol. 35, no. 2, pp. 124–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. M. C. Mendoz, J. Ruiz-Contreras, J. L. Vivanco et al., “Respiratory virus infections in children with cancer or HIV infection,” Journal of Pediatric Hematology/Oncology, vol. 28, no. 3, pp. 154–159, 2006. View at Publisher · View at Google Scholar
  51. J. Moyes, C. Cohen, M. Pretorius et al., “Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011,” The Journal of Infectious Diseases, vol. 208, supplement 3, pp. S217–S226, 2013. View at Publisher · View at Google Scholar
  52. C. B. Hall, K. R. Powell, N. E. MacDonald et al., “Respiratory syncytial viral infection in children with compromised immune function,” The New England Journal of Medicine, vol. 315, no. 2, pp. 77–81, 1986. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Navas, E. Wang, V. de Carvalho, and J. Robinson, “Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children,” Journal of Pediatrics, vol. 121, no. 3, pp. 348–354, 1992. View at Publisher · View at Google Scholar · View at Scopus
  54. E. E. Wang, B. J. Law, and D. Stephens, “Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection,” The Journal of Pediatrics, vol. 126, no. 2, pp. 212–219, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Murphy, M. J. Lempert, and L. B. Epstein, “Decreased level of T cell receptor expression by Down syndrome (trisomy 21) thymocytes,” American Journal of Medical Genetics, vol. 37, supplement S7, pp. 234–237, 1990. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Murphy, W. Hyun, B. Hunte, A. D. Levine, and L. B. Epstein, “A role for tumor necrosis factor-α and interferon-γ in the regulation of interleukin-4-induced human thymocyte proliferation in vitro. Heightened sensitivity in the Down syndrome (trisomy 21) thymus,” Pediatric Research, vol. 32, no. 3, pp. 269–276, 1992. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. C. M. De Hingh, P. W. Van Der Vossen, E. F. A. Gemen et al., “Intrinsic abnormalities of lymphocyte counts in children with down syndrome,” Journal of Pediatrics, vol. 147, no. 6, pp. 744–747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. B. L. P. Bloemers, A. M. van Furth, M. E. Weijerman et al., “Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis—a prospective birth-cohort study,” Pediatrics, vol. 120, no. 4, pp. e1076–e1081, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. S. S. Blanchard, M. Gerrek, C. Siegel, and S. J. Czinn, “Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis,” Pediatric Transplantation, vol. 10, no. 7, pp. 826–829, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. The IMpact-RSV Study Group, “Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants,” Pediatrics, vol. 102, no. 3, part 1, pp. 531–537, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. American Academy of Pediatrics. Committee on Infectious Disease, “Policy statement—modified recommendations for use of palivizumab for prevention of respiratorysyncytial virus infections,” Pediatrics, vol. 124, no. 6, pp. 1694–1701, 2009. View at Google Scholar
  62. “Raccomandazioni della società italiana di neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS),” Acta Neonatologica e Pediatrica, vol. 18, pp. 19–30, 2004.
  63. Grupo de trabajo de la Guía de Práctica Clínica sobre la Bronquiolitis Aguda, “Guía de práctica clínica sobre la bronquiolitis aguda,” Guías de Práctica Clínica en el SNS AATRM Núm. 2007/05, Plan de Calidad para el Sistema Nacional de Salud (SNS) del Ministerio de Sanidad y Política Social, 2010. View at Google Scholar
  64. Joint statement with the Fetus and Newborn Committee, “Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants,” Paediatrics and Child Health, vol. 4, no. 7, pp. 474–489, 1999. View at Google Scholar
  65. BC Guidelines for RSV Infection Immunoprophylaxis 2012—13 RSV Season, http://www.childhealthbc.ca/.
  66. “Canadian Pediatric Society Statement Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants,” Paediatrics and Child Health, vol. 4, no. 7, 1999.
  67. M. Mori, H. Kawashima, H. Nakamura et al., “Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan,” Journal of Infection and Chemotherapy, vol. 17, no. 2, pp. 254–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Manzoni, M. Leonessa, D. Farina, and G. Gomirato, “Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting,” Pediatric Transplantation, vol. 11, no. 4, pp. 456–457, 2007. View at Publisher · View at Google Scholar · View at Scopus